WO2023196821A3 - Targeting neuropod cell gucy2c to control visceral pain and appetite - Google Patents

Targeting neuropod cell gucy2c to control visceral pain and appetite Download PDF

Info

Publication number
WO2023196821A3
WO2023196821A3 PCT/US2023/065341 US2023065341W WO2023196821A3 WO 2023196821 A3 WO2023196821 A3 WO 2023196821A3 US 2023065341 W US2023065341 W US 2023065341W WO 2023196821 A3 WO2023196821 A3 WO 2023196821A3
Authority
WO
WIPO (PCT)
Prior art keywords
gucy2c
visceral pain
appetite
neuropod
targeting
Prior art date
Application number
PCT/US2023/065341
Other languages
French (fr)
Other versions
WO2023196821A2 (en
Inventor
Scott Waldman
Adam Snook
Joshua BARTON
Tyler Alexander
Manuel COVARRUBIAS
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of WO2023196821A2 publication Critical patent/WO2023196821A2/en
Publication of WO2023196821A3 publication Critical patent/WO2023196821A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The use of GUCY2C agonists in combination with PDE3 inhibitors in methods of treating the individual who has been identified as experiencing chronic visceral pain or in methods of suppressing appetite are disclosed. Compositions or kits comprising GUCY2C agonists and PDE3 inhibitors for use in methods of treating of an individual who has been identified as experiencing chronic visceral pain or in methods of suppressing appetite are disclosed.
PCT/US2023/065341 2022-04-04 2023-04-04 Targeting neuropod cell gucy2c to control visceral pain and appetite WO2023196821A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263327352P 2022-04-04 2022-04-04
US63/327,352 2022-04-04

Publications (2)

Publication Number Publication Date
WO2023196821A2 WO2023196821A2 (en) 2023-10-12
WO2023196821A3 true WO2023196821A3 (en) 2023-11-16

Family

ID=88243582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/065341 WO2023196821A2 (en) 2022-04-04 2023-04-04 Targeting neuropod cell gucy2c to control visceral pain and appetite

Country Status (1)

Country Link
WO (1) WO2023196821A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258593A1 (en) * 2003-01-28 2006-11-16 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US20120308583A1 (en) * 2003-02-10 2012-12-06 Thomas Jefferson University Use of gcc ligands
WO2018119191A1 (en) * 2016-12-21 2018-06-28 Ironwood Pharmaceuticals Inc. Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258593A1 (en) * 2003-01-28 2006-11-16 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US20120308583A1 (en) * 2003-02-10 2012-12-06 Thomas Jefferson University Use of gcc ligands
WO2018119191A1 (en) * 2016-12-21 2018-06-28 Ironwood Pharmaceuticals Inc. Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide

Also Published As

Publication number Publication date
WO2023196821A2 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
EP4234030A3 (en) Pd-1/pd-l1 inhibitors
WO2006124892A3 (en) Modulators of alpha-synuclein toxicity
EP2484679A3 (en) N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors
WO2008076278A8 (en) Methods of cancer treatment with igf1r inhibitors
WO2007097940A3 (en) Reca inhibitors with antibiotic activity, compositions and methods of use
WO2010038086A8 (en) P38 map kinase inhibitors
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
EP2476679A3 (en) Substituted triazoles useful as AXL inhibitors
WO2008060813A3 (en) High affinity antibody antagonists of interleukin-13 receptor alpha 1
MY158106A (en) Inhibitors of e1 activating enzymes
UA74325C2 (en) HETEROCYCLIC INHIBITORS р38, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND A METHOD FOR TREATMENT WITH THEIR USE
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
WO2009114725A3 (en) Mobilization op hematopoietic stem cells using cdc42 inhibitors
MXPA05005398A (en) Target for therapy of cognitive impairment.
WO2007062413A3 (en) Use of parp-1 inhibitors
WO2010056378A3 (en) Extracellular matrix compositions for the treatment of cancer
EP4011376A3 (en) Combination of an alk inhibitor and an egfr inhibitor for treating cancer
CA2558429A1 (en) Compositions and methods for preventing or treating an inflammatory response
AU2020258568A8 (en) CD73 inhibitors
MX2021011524A (en) Prmt5 inhibitors and uses thereof.
WO2021142448A3 (en) Tgf-beta inhibitors and use thereof
WO2006130493A8 (en) Heterocycles useful as modulators of ion channels
MX2023011883A (en) Combination therapies with cbl-b inhibitor compounds.
WO2023196821A3 (en) Targeting neuropod cell gucy2c to control visceral pain and appetite
WO2021216687A9 (en) Peptides for the treatment of covid-19

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23785577

Country of ref document: EP

Kind code of ref document: A2